Therapy Area topics
A convincing hit puts approval, and potentially partnerships, on the table.
Central Nervous System
Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.
The mid-stage Nash pipeline plays host to mechanisms both evidence-backed and unproven, with plenty of data on the horizon.
But supply problems are getting worse.
But large gains for some big pharma players flatter the overall figures.
The promise of fast timelines and early revenues lure a new investor into digital medicine.
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.